Find information on common issues.
Ask questions and find answers from other users.
Suggest a new site feature or improvement.
Check on status of your tickets.
The Importance of Zeta Potential for Drug/Gene Delivery in Nanomedicine
11 Apr 2012 | Online Presentations | Contributor(s): James Leary
BME 695L Lecture 1: Need for New Perspectives on Medicine
31 Aug 2011 | Online Presentations | Contributor(s): James Leary
See references below for related reading.
1.1 Nanotechnology – Why is something so small so big?
1.1.1 Definitions of nanotechnology based on size
1.1.2 A “bottoms up” rather than “tops down” approach
1.1.3 The nanoworld challenges our perspectives on size
1.2 The Progression of Medicine
1.2.1 Conventional "modern" medicine
1.2.2 "Personalized" or "molecular" medicine
1.2.3 Nanomedicine "single-cell" medicine
1.3 How Conventional Medicine Works for Diagnosis of Disease
1.3.1 Identification of the "diseased state"
1.3.2 Simple measurements of body structure and function
1.3.3 Follow-up clinical tests
1.3.4 Internal examinations by non-invasive in-vivo imaging
1.3.5 Molecular tests for specific gene properties
1.3.6 Comparison of individual results with "normal ranges"
1.4 How Conventional Medicine Works for Treatment of Disease
1.4.1 Stabilization of patient – "heal thyself"
1.4.2 Surgical repair of injuries
1.4.3 Treatment with drugs locally
1.4.4 Treatment with drugs systemically
1.4.5 Treatment with targeted therapies
1.5 Factors Limiting the Progress of Medicine
1.6 Some Specific Problems with Conventional Medicine
1.6.1 Consequences of waiting for patient symptoms
1.6.2 Trained people and modern drugs are expensive
1.6.3 Diagnostic technologies, if available, are still relatively primitive and/or expensive
1.6.4 Crude targeting of drugs
1.7 What is the Basis for Nanomedicine?
1.7.1 Creation of nano-sized tools
1.7.2 These nanotools permit single-cell medicine
1.7.3 These “nanomedical systems” can be “smart” devices
1.8 Some ways that nanotechnologies will impact on healthcare
1.8.1 Nanomedicine will be “pro-active” rather than “reactive” medicine
1.8.2 Possibility of "regenerative medicine"
1.8.3 Blurring of distinction between prevention and treatment
Engineering Nanomedical Systems
5.0 out of 5 stars
06 Mar 2006 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 13: Assessing Zeta Potentials
0.0 out of 5 stars
29 Oct 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 15: Nanodelivery of therapeutic genes & molecular biosensor feedback control systems
30 Oct 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 10: Nanomaterials for core design
26 Sep 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 1: Need for New Perspectives on Medicine
03 Aug 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 4: Designing "Theragnostic" Systems
04 Sep 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 2: Basic Concepts of Nanomedical Systems
28 Aug 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 17: Assessing nanotoxicity at the single cell level
06 Nov 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 5: Cell Targeting
12 Sep 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 16: Assessing drug efficacy at the single cell level
02 Nov 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 20: GMP and issues of quality control manufacture of nanodelivery systems
15 Nov 2007 | Online Presentations | Contributor(s): James Leary
16 Nov 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 8: Technologies for measuring nanomedical systems on/within cells
24 Sep 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 18: Designing nanodelivery systems for in-vivo use
12 Nov 2007 | Online Presentations | Contributor(s): James Leary
KIST/PU Multi-Component, Multi-Functional Nanomedical Systems for Drug/Gene Delivery
23 Oct 2007 | Online Presentations | Contributor(s): James Leary
Nanotechnologies, Science and Society: Promises and Challenges
10 May 2007 | Online Presentations | Contributor(s): James Leary
BME 695N Lecture 14: Challenges of proper drug dosing with nanodelivery systems
BME 695N Lecture 3: Overview of Basic Nanomedical Systems Design
29 Aug 2007 | Online Presentations | Contributor(s): James Leary
BME 695L Lecture 2: Designing Nanomedical Systems
2.1 Elements of good engineering design
2.1.1 Whenever possible, use a general design that has already been tested
2.1.2 Whenever possible, take advantage of “biomimicry” – Nature has tried many designs!
2.1.3 Avoid “general purpose” design. Use multiple specific molecules to do specific tasks.
2.1.4 Control the order of molecular assembly to control the order of events
2.1.5 Therefore, perform the nano assembly in reverse order to the desired order of events
2.2 Building a nanodevice
2.2.1 Choice of core materials
2.2.2 Add drug or therapeutic gene
2.2.3 Add molecular biosensors to control drug/gene delivery
2.2.4 Add intracellular targeting molecules
2.2.5 Result is multi-component, multi-functional nanomedical device
2.2.6 For use, design to de-layer, one layer at a time
2.2.7 The multi-step drug/gene delivery process in nanomedical systems
2.3 The challenge of drug/gene dosing to single cells
2.3.1 Precise targeting of drug delivery system while protecting non-targeted cells from exposure to the drug
2.3.2 How to minimize mis-targeting
2.3.3 How to deliver the right dose per cell
2.3.4 One possible solution – in situ manufacture of therapeutic genes
2.4 Bridging the gap between diagnostics and therapeutics
2.4.1 how conventional medicine is practiced in terms of diagnostics and therapeutics
2.4.2 the consequences of separating diagnostics and therapeutics
2.4.3 a new approach – "theragnostics" (or "theranostics")
2.5 Examples of current theragnostic systems
2.5.1 example 1: Rituxan ("Rituximab)(an example of not using diagnostics to guide the therapy)
2.5.2 example 2: Herceptin ("terastuzumab")
2.5.3 example 3: Iressa ("Gefitinib)
2.5.4 other examples
2.6 How theragnostics relates to Molecular Imaging
2.6.1 conventional imaging is not very specific
2.6.2 types of In-vivo Imaging
184.108.40.206 X-rays, CAT (Computed Axial Tomography) scans
220.127.116.11 MRI (magnetic Resonance Imaging)
18.104.22.168 PET (Positron Emission Tomography) scans
2.6.3 "molecular imaging" of nanoparticles in-vivo for diagnostics/monitoring of therapeutics
2.8 Engineering nanomedical systems for simultaneous molecular imaging
2.8.1 using nanomedical cores for MRI contrast agents
2.8.2 difficulties in using PET probes for nanomedical devices
2.8.3 using cell-specific probes for molecular imaging of nanomedical devices
2.8.4 breaking the "diffraction limit" – new nano-level imaging modalities
2.9 Theragnostic nanomedical devices
2.9.1 using nanomedical devices to guide separate therapeutic device
2.9.2 when might we want to combine diagnostics and therapeutics?
BME 695N Lecture 6: Rare-event targeting of cells in-vitro and in-vivo
BME 695N Lecture 21: FDA and EPA Regulatory Issues
27 Nov 2007 | Online Presentations | Contributor(s): James Leary
Ethics of Stem Cells and Therapeutic Cloning
BME 695L Lecture 15: GMP and Issues of Quality Control Manufacture of Nanodelivery Systems
02 Dec 2011 | Online Presentations | Contributor(s): James Leary
15.1.1 What does cGMP mean?
15.1.2 Why GMP? Controlling processes means more predictable outcomes…
15.1.4 What can be learned from the semi-conductor industry clean-room and manufacturing?
15.1.5 What doesn’t fit this paradigm?
15.2 cGMP-level manufacturing
15.2.1 Predictable methods lead to predictable products
15.2.2 The CFR (Code of Federal Regulations) sections on GMPs
15.2.3 What is covered under cGMP?
15.3.1 So what is special about biomanufacturing?
15.3.2 Nano-clean water necessary for nano-pharmaceuticals
15.3.3 Contaminants at the nano-level
15.3.4 Can you scale up the process?
15.4 Some quality control issues – how to test
15.4.1 Correctness of size – size matters!
15.4.2 Composition – atomic level analyses
15.4.3 Monodispersity versus agglomeration
15.4.4 Order and correctness of layers2
15.4.5 Correctness of zeta potentials
15.4.6 Does the nanomedical system contain the correct payload?
15.4.7 Targeting (and mis-targeting) specificity and sensitivity